Last updated on September 2018

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Brief description of study

This prospective, post marketing, observational, Noninterventional Study (NIS) is designed to compare drug persistence in patients treated with Certolizumab Pegol (CZP) and patients treated with any other subcutaneously (sc) administered Tumor Necrosis Factor (TNF) inhibitor.

Clinical Study Identifier: NCT01764321

Contact Investigators or Research Sites near you

Start Over

UCB Cares

Donaueschingen, Germany